Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 3/20 | 0.36 |
| ▸ | PRKCG | P05129 | 1/20 | 0.36 |
| ▸ | PRKCB | P05771 | 1/20 | 0.36 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.36 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 4/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | SCN1A | P35498 | 1/20 | 0.33 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.33 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26135802 | 0.90 | PRKCA (0.37) | PRKCAPRKCGPRKCBPRKCEPRKCD | |
| SCHEMBL18670631 | 0.90 | PRKCA (0.37) | PRKCAPRKCGPRKCBPRKCEPRKCD | |
| SCHEMBL26129664 | 0.90 | PRKCA (0.37) | PRKCAPRKCGPRKCBPRKCEPRKCD | |
| SCHEMBL18670633 | 0.90 | PRKCA (0.37) | PRKCAPRKCGPRKCBPRKCEPRKCD | |
| SCHEMBL29678706 | 0.87 | HPGD (0.37) | PRKCAPRKCGPRKCBPRKCEPRKCD | |
| SCHEMBL18670630 | 0.80 | HPGD (0.38) | PRKCAPRKCGPRKCBPRKCEPRKCD | |
| SCHEMBL18670654 | 0.80 | HPGD (0.38) | PRKCAPRKCGPRKCBPRKCEPRKCD | |
| SCHEMBL18670648 | 0.79 | SCN1A (0.38) | PRKCAPRKCGPRKCBPRKCEPRKCD | |
| SCHEMBL18670646 | 0.79 | SCN1A (0.38) | PRKCAPRKCGPRKCBPRKCEPRKCD | |
| SCHEMBL31308611 | 0.79 | POLB (0.40) | PRKCAPRKCGPRKCBPRKCEPRKCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12370208-B2 | Adenosine derivative and pharmaceutical composition comprising the same | BRII BIOSCIENCES, INC. (US) | 2025-07-29 | — | — | US | disclosed |
| US-20220288098-A1 | ADENOSINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | BRII BIOSCIENCES, INC. | 2022-09-15 | — | — | US | disclosed |
| EP-4003369-A1 | ADENOSINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | Brii Biosciences, Inc. (US) | 2022-06-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12370208-B2 | Adenosine derivative and pharmaceutical composition comprising the same | ADAR, ADA, ADORA2A | PRKCA 1994/4885PRKCG 1840/4885PRKCB 1700/4885 |
| US-20220288098-A1 | ADENOSINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | ADAR, ADA, ADORA2A | PRKCA 1994/4885PRKCG 1840/4885PRKCB 1700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.